NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · IEX Real-Time Price · USD
1.820
+0.090 (5.20%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.

Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis.

The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.

NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics logo
Country Israel
Founded 2017
IPO Date Dec 9, 2021
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Alon Ben-Noon

Contact Details

Address:
11 Hamenofim St., Building B
Herzliya, L3 4672562
Israel
Phone 972-9-9531142
Website neurosense-tx.com

Stock Details

Ticker Symbol NRSN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001875091
CUSIP Number M74240108
ISIN Number IL0011809592
SIC Code 2834

Key Executives

Name Position
Alon Ben-Noon Co-Founder, Chief Executive Officer and Director
Or Eisenberg Chief Financial Officer
Dr. Ferenc Tracik M.D. Chief Medical Officer
Hagit Binder Chief Operation Officer
Dr. Niva Russek-Blum Ph.D. Chief Technology Officer
Yael Barak Vice President of Quality and Compliance
Keren Pushett Head of Human Resources
Eidan Loushi C.R.A.

Latest SEC Filings

Date Type Title
Feb 22, 2024 6-K Report of foreign issuer
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 6-K Report of foreign issuer
Jan 9, 2024 6-K Report of foreign issuer
Jan 9, 2024 6-K Report of foreign issuer
Dec 27, 2023 424B3 Prospectus
Dec 27, 2023 6-K Report of foreign issuer
Dec 21, 2023 6-K Report of foreign issuer
Dec 14, 2023 424B3 Prospectus